Skip to main content
FRNMFreenome, Inc.Sell4.9·$13.82+2.14%
SellModerate Confidence
Investment thesis

Freenome trades at a rich valuation with no clear competitive moat, but its recent pullback appears to be occurring within a still-rising 200-day trend, with peer-relative growth positioning and early positive news sentiment offering tentative support.

Thesis pillars

  • No Competitive MoatStable
  • Expensive Valuation FlagImproving
  • Pullback In Rising TrendImproving
  • +2 more pillars — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Freenome, Inc. (FRNM) Stock Analysis

SellGrowthQualityModerate Confidence

Healthcare · Diagnostics & Research

Sell if holding. Engine safety override at $13.82: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Rich valuation.

Perceptive Capital Solutions Corp (trading as FRNM) was a blank-check special purpose acquisition company formed in March 2024 to pursue a healthcare or life-sciences business combination, sponsored by an affiliate of Perceptive Advisors. It held $91.9 million in trust as of... Read more

$13.82+5.9% A.UpsideScore 4.9/10#26 of 32 Diagnostics & Research
QualityF-score4 / 9FCF yield
Stop $12.87Target $14.66(analyst − 15%)A.R:R 0.4:1
Analyst target$17.25+24.8%4 analysts
$14.66our TP
$13.82price
$17.25mean
$18

Sell if holding. Engine safety override at $13.82: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.

Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About Freenome, Inc.

About Freenome, Inc.

Perceptive Capital Solutions Corp raised $86.25 million in its June 2024 IPO plus a concurrent private placement, placing $91.9 million in trust as of December 31, 2025 to fund a healthcare-focused business combination. The company is sponsored by an affiliate of Perceptive Advisors, a life-sciences investment firm with more than $9.5 billion in regulatory assets under management and stakes in 234 companies as of December 31, 2025. On December 5, 2025, it signed a Business Combination Agreement with Freenome Holdings, Inc.

As a blank-check company, Perceptive Capital Solutions Corp generated no operating revenue; its only assets were cash and investments held in a trust account established with Continental Stock Transfer & Trust Company as trustee. The company's management team — Chairman Joseph Edelman (founder of Perceptive Advisors), CEO Adam Stone (Perceptive's Chief Investment Officer), and Chief Business Officer Michael Altman — previously sponsored four other ARYA Sciences Acquisition SPACs, which completed mergers with Immatics (now IMTX), Cerevel Therapeutics (acquired by AbbVie in 2024), and Nautilus Biotechnology (now NAUT), while a fifth, ARYA V, liquidated in 2023 without finding a target. The company had 24 months from its IPO closing to complete an initial business combination representing at least 80% of trust-account net assets, structured so the post-combination company would generally acquire 100% of the target's equity, though existing shareholders could retain a minority position depending on deal terms. Affiliates of Perceptive Advisors and board members held 2,156,250 Founder Shares that would lose most of their value if no combination closed in time.

Show full overview

That combination has since closed: an 8-K filed July 24, 2026 discloses that on July 20, 2026, Perceptive Capital Solutions Corp completed its business combination with Freenome Holdings, Inc., first domesticating from a Cayman Islands exempted company into a Delaware corporation before merging Freenome into a wholly-owned subsidiary. The combined entity now trades on Nasdaq under the ticker FRNM as Freenome, Inc., meaning the blank-check structure and trust-account mechanics described in this 10-K no longer reflect the company's current status — the entity has transitioned into an operating company, and its next annual report should describe Freenome's actual liquid-biopsy diagnostics business rather than SPAC search activity.

See also: Healthcare · Diagnostics & Research

From Freenome, Inc.'s most recent 10-K filing, extracted August 9, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-08-21

Recent Developments — Freenome, Inc.

Material events (past 30 days)

  • 8K Jul 24, 2026 HIGH Item 5.01: Perceptive Capital Solutions Corp completed its business combination with Freenome Holdings, Inc. on July 20, 2026, domesticating as a Delaware corporation and merging Freenome into a wholly-owned subsidiary; the combined company continues trading on Nasdaq as Freenome, Inc. under ticker FRNM. Chang

Generated 2026-08-21T18:12:34Z.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.2 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)-5.6
Mkt Cap$1.4B
EV/EBITDA-9.4
Profit Mgn0.0%
ROE
Rev Growth971.6%
Beta0.35
DividendNone
Rating analysts4

Quality Signals

Piotroski F4/9

Material Events(8-K, last 90d)

  • 2026-07-24Item 5.01HIGH
    Perceptive Capital Solutions Corp completed its business combination with Freenome Holdings, Inc. on July 20, 2026, domesticating as a Delaware corporation and merging Freenome into a wholly-owned subsidiary; the combined company continues trading on Nasdaq as Freenome, Inc. under ticker FRNM. Change of control.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Net Margin
0.0
Piotroski F
4.4
Moat
5.0
Current Ratio
6.7
No competitive moat

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Analyst Target
6.0
Low model confidence on this dimension (33%).

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
0.0
Quality Rank
5.0
Growth Rank
10.0
Industry growth leader
GatesA.R:R 0.4 < 1.5@spot8K FLAG 5.01Momentum 6.6>=5.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
83 · Overbought
20D MA 50D MA 200D MADEATH CROSSSupport $9.97Resistance $14.13

Price Targets

$13
$15
A.Upside+5.9%
A.R:R0.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.2 < 4.0)
! asymmetry at 0.4 (below the engine's 1.5 threshold)@spot

Earnings

We could not retrieve earnings history for FRNM.
The company may be recently listed, pre-revenue, or its beat/miss record wasn't available from our source this run. Earnings signals feed the Growth and Catalyst score dimensions — absence here doesn't affect other dimensions.

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is FRNM stock a buy right now?

Sell if holding. Engine safety override at $13.82: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $12.87. Score 4.9/10, moderate confidence.

What is the FRNM stock price target?

Take-profit target: $14.66 (+5.9% upside). Prior stop was $12.87. Stop-loss: $12.87.

What are the risks of investing in FRNM?

Quality below floor (3.2 < 4.0).

Is FRNM overvalued or undervalued?

Freenome, Inc. trades at a P/E of N/A (forward -5.6). TrendMatrix value score: 3.6/10. Verdict: Sell.

0
What does Freenome, Inc. do?Perceptive Capital Solutions Corp (trading as FRNM) was a blank-check special purpose acquisition company formed in...

Perceptive Capital Solutions Corp (trading as FRNM) was a blank-check special purpose acquisition company formed in March 2024 to pursue a healthcare or life-sciences business combination, sponsored by an affiliate of Perceptive Advisors. It held $91.9 million in trust as of December 31, 2025 and, per a July 2026 8-K, completed its business combination with Freenome Holdings, Inc. on July 20, 2026, with the combined company continuing to trade under the FRNM ticker as Freenome, Inc.

Related stocks: CDNA (CareDx, Inc.) · CSTL (Castle Biosciences, Inc.) · VCYT (Veracyte, Inc.) · SHC (Sotera Health Company) · BLLN (BillionToOne, Inc.)
Home Stocks FRNM

Latest news

Latest News

Benzinga3d agoCONCERN
Benzinga1d ago
Benzinga3d ago
Benzinga4d ago
Benzinga4d ago
Benzinga7d ago
Benzinga9d ago
Benzinga25d ago